Bedrocan obtains GMP certificate for Danish facility

The new Danish production site recently passed a GMP inspection, carried out by the Danish Medicines Agency DKMA, with flying colours. The Danish authorities have now granted the GMP certificate that allows Bedrocan to start cultivation. The Bedrocan board of directors would like to congratulate all employees involved in achieving this enormous milestone. The cultivation activities are now in full swing to supply the first customers in 2025. The recruitment of new staff, including processors and packers, will also start shortly.

First audit

“The fact that the inspectors were satisfied with their first audit makes it something very special for us as a company and our industry. The fact that our Dutch knowledge and experience has been transferred 1-on-1 to another jurisdiction is evidence of an unparalleled level of professionalism,” CEO Jaap Erkelens proudly explains. Bedrocan is a cannabis grower of Dutch origin who, in addition to two cultivation locations in the Netherlands, has also delivered a brand new facility in Køge (Denmark) and is now also working on breathing new life into the former production facility in Canada. ‘I am convinced’, Erkelens continues, ‘that we can once again use this Danish experience elsewhere in the world as the Bedrocan concept for cannabis medicines.’

Annual capacity

The certificate was obtained just before the end of 2024 and the staff could not have imagined a better way to end both the year and the project. The Danish facility will aim to meet the growing demand for Bedrocan’s standardised medicinal cannabis. The new production location has an annual capacity of 2,300 kilos.